home / stock / vtrs / vtrs news


VTRS News and Press, Viatris Inc. From 08/08/23

Stock Information

Company Name: Viatris Inc.
Stock Symbol: VTRS
Market: NASDAQ
Website: viatris.com

Menu

VTRS VTRS Quote VTRS Short VTRS News VTRS Articles VTRS Message Board
Get VTRS Alerts

News, Short Squeeze, Breakout and More Instantly...

VTRS - Viatris Q2 2023 Earnings Review: Buy, Sell, Or Hold After Mixed Results?

2023-08-08 10:34:31 ET Summary Viatris Inc. announced its Q2 2023 earnings yesterday. Total net sales were $3.9bn, and free cash flow $447m. While like-for-like product sales grew year-on-year, EBITDA and FCF declined significantly, owing to increased SG&A and R&D spending...

VTRS - Viatris Inc. (VTRS) Q2 2023 Earnings Call Transcript

2023-08-07 12:13:10 ET Viatris Inc. (VTRS) Q2 2023 Earnings Call Transcript August 07, 2023 08:30 AM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chi...

VTRS - Viatris multiple sclerosis therapy accepted for FDA review

2023-08-07 08:07:17 ET More on Viatris Viatris: Currently Appealing Only To Income-Focused Investors Viatris: Developing Into A Fantastic Investment Opportunity Despite Its Valuation, Viatris Is Still A Hold Viatris posts first topline beat in over a year as ...

VTRS - Viatris posts first topline beat in over a year as Q2 revenue improves

2023-08-07 07:43:11 ET More on Viatris Viatris: Currently Appealing Only To Income-Focused Investors Viatris: Developing Into A Fantastic Investment Opportunity Despite Its Valuation, Viatris Is Still A Hold Viatris: Won't Take Much To Move The Needle ...

VTRS - Viatris beats Q2 top and bottom line estimates; reaffirms FY23 outlook

2023-08-07 07:04:57 ET Viatris press release ( NASDAQ: VTRS ): Q2 GAAP EPS of $0.22 beats by $0.02 . Revenue of $3.92B (-4.9% Y/Y) beats by $60M . Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; a...

VTRS - Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] PR Newswire Reports Total Revenues of $3.92 Billion ; U.S. GAAP Net Earnings of $264 Million ; Adjusted EBITDA of $1.31 Billion ; U.S....

VTRS - Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis PR Newswire FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase...

VTRS - Earnings week ahead: Disney, Palantir, Plug Power, Roblox, Rivian and more

2023-08-06 08:01:00 ET The second week of August promises to be an eventful one for investors as a slew of major companies is set to report quarterly results. Among the headliners, Disney ( NYSE: DIS ) is prehaps the most well-known company due to report. The schedule also incl...

VTRS - Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years

2023-08-04 08:20:00 ET Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out which dividend stock has what it takes to keep paying out for years and ...

VTRS - Viatris Announces Launch of Breyna(TM) (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kinde

Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva PR Newswire Lau...

Previous 10 Next 10